An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea Limited (CKDXF – Research Report) received a Sell rating and a A$0.05 price target from Bell Potter analyst Thomas Wakim yesterday. The ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

Shares of Opthea Limited (NASDAQ:OPT – Get Free Report) have been assigned an average recommendation of “Hold” from the six ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...